Circassia Pharmaceuticals PLC (CSSPF)

Circassia Pharmaceuticals Stock Analysis & Ratings

CSSPF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.46 - $0.48
Previous Close$0.48
Average Volume (3M)3.00
Market Cap$201.27M
P/E Ratio41.4
Next EarningsSep 29, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score8
EPS (TTM)0.01

Circassia Pharmaceuticals News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Circassia Pharmaceuticals’s price range in the past 12 months?
Circassia Pharmaceuticals lowest stock price was $0.46 and its highest was $0.48 in the past 12 months.
    What is Circassia Pharmaceuticals’s market cap?
    Circassia Pharmaceuticals’s market cap is $201.27M.
      What is Circassia Pharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Circassia Pharmaceuticals?
      Not enough analysts have published a price target to provide an average price target.
      When is Circassia Pharmaceuticals’s upcoming earnings report date?
      Circassia Pharmaceuticals’s upcoming earnings report date is Sep 29, 2022 which is in 134 days.
        How were Circassia Pharmaceuticals’s earnings last quarter?
        Circassia Pharmaceuticals released its earnings results on Mar 22, 2022. The company reported $0.014 earnings per share for the quarter, beating the consensus estimate of N/A by $0.014.
          Is Circassia Pharmaceuticals overvalued?
          According to Wall Street analysts Circassia Pharmaceuticals’s price is currently Overvalued.
            Does Circassia Pharmaceuticals pay dividends?
            Circassia Pharmaceuticals does not currently pay dividends.
            What is Circassia Pharmaceuticals’s EPS estimate?
            Circassia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Circassia Pharmaceuticals have?
            Circassia Pharmaceuticals has 419,320,000 shares outstanding.
              What happened to Circassia Pharmaceuticals’s price movement after its last earnings report?
              Circassia Pharmaceuticals reported an EPS of $0.014 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Circassia Pharmaceuticals?
                Currently, no hedge funds are holding shares in CSSPF


                Circassia Pharmaceuticals Stock Analysis

                Smart Score
                Price Target
                No data currently available
                The Circassia Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Circassia Pharmaceuticals PLC

                Circassia Group PLC is a biotechnology company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of revenue from the US and also has a presence in EU, Asia Pacific and Rest of world.

                Similar Stocks
                Price & Change
                Allied Minds
                4d Pharma
                ReNeuron Group

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis